<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159727</url>
  </required_header>
  <id_info>
    <org_study_id>18-22 Medibiote 1</org_study_id>
    <nct_id>NCT04159727</nct_id>
  </id_info>
  <brief_title>Gut Microbiota Dysbiosis and Translocation During IBD and Parkinson</brief_title>
  <acronym>Medibiote1</acronym>
  <official_title>Gut Microbiota Dysbiosis and Translocation Within Patients Suffering From Diseases Associated With Increased Intestinal Barrier Permeability : IBD and Parkinson</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Européen Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Européen Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory bowel diseases (IBD) and Parkinson disease (PD) are complex and multifactorial&#xD;
      pathologies. Gut microbiota seems to play an active role. Indeed the digestive microbiota of&#xD;
      patients with IBD or PD exhibits different compositions compared with asymptomatic subjects.&#xD;
&#xD;
      Bacterial translocation from gut to blood has been reported.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators designed a case-control study to investigate the digestive microbiota and&#xD;
      bacterial translocation during IBD and PD. The investigators want to evaluate gut microbiota&#xD;
      bacteria involved in dysbiosis and bacterial translocation during IBD and PD. The&#xD;
      investigators want to identify bacterial populations that can serve as biomarkers for&#xD;
      clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Actual">February 13, 2020</completion_date>
  <primary_completion_date type="Actual">February 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>16S RNA sequencing in stool sample</measure>
    <time_frame>2 years</time_frame>
    <description>16S RNA sequencing to identify species constituting the microbiota in the stool</description>
  </primary_outcome>
  <primary_outcome>
    <measure>16S RNA sequencing in blood sample</measure>
    <time_frame>2 years</time_frame>
    <description>16S RNA sequencing to identify species constituting the microbiota in the blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool quantification of key bacteria associated with intestinal barrier permeability.</measure>
    <time_frame>2 years</time_frame>
    <description>To determine stool rates of Faecalibacterium prausnitzii, Akkermansia muciniphila, Bacteroides fragilis, Clostridium difficile, Mycobacterium avium paratuberculosis and Escherischia coli by qPCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood quantification of key bacteria associated with intestinal barrier permeability.</measure>
    <time_frame>2 years</time_frame>
    <description>To determine blood rates of Faecalibacterium prausnitzii, Akkermansia muciniphila, Bacteroides fragilis, Clostridium difficile, Mycobacterium avium paratuberculosis and Escherischia coli by qPCR</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>IBD or PD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients suffering from IBD 10 patients suffering from PD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 asymptomatic subjects matched to patients on age, sexe and BMI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stool and blood analysis</intervention_name>
    <description>High throughput sequencing and quantitative PCR</description>
    <arm_group_label>Asymptomatic subjects</arm_group_label>
    <arm_group_label>IBD or PD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PD patients : age &lt; or = 60 years&#xD;
&#xD;
          -  asymptomatic subjects : no chronic disease&#xD;
&#xD;
          -  asymptomatic subjects : no treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe anemia (Hb&lt;7g/L)&#xD;
&#xD;
          -  people who don't read french&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  people treated by antibiotic, probiotic or prebiotic during the 2 month before&#xD;
             inclusion&#xD;
&#xD;
          -  people with any diagnosed or treated pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe HALFON, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European Hospital</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du Rhone</state>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gut microbiota</keyword>
  <keyword>Bacterial translocation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

